



**Minutes of the Integrated Medicines Optimisation Committee (IMOC)**  
**Held on Wednesday 2<sup>nd</sup> July 2025 11:30-13:30**  
**Via Microsoft Team**

| Attendees present: | Time of attendance (if not present for full meeting) | Invited Attendees:         |                                                                                               |
|--------------------|------------------------------------------------------|----------------------------|-----------------------------------------------------------------------------------------------|
| ✓                  |                                                      | David Warwicker (DW)       | Medical Lead for Medicines Optimisation ( <b>chair</b> )                                      |
| ✓                  |                                                      | Heidi Taylor (HT)          | SYICB Medicines Optimisation Programme Director (Clinical Effectiveness, Quality and Safety)  |
| ✓                  |                                                      | Alex Molyneux (AJM)        | NHS SY ICS Chief Pharmacy Officer                                                             |
|                    |                                                      | Chris Bland (CB)           | Chair community pharmacy South Yorkshire                                                      |
| ✓                  | Arrived 13:00                                        | Govinder Bhogal (GOVB)     | Programme Director for Medicines Optimisation (Pathways Redesign and Population Health)       |
| ✓                  |                                                      | Chris Lawson (CL)          | SYICB Medicines Optimisation Programme Director (Strategy & Delivery)                         |
| ✓                  |                                                      | Charlotte McMurray (CM)    | SYICB Medicines Optimisation Programme Director (Pharmacy Integration and Development)        |
| ✓                  |                                                      | Ashley Hill (AH)           | SYICB Senior Medicines Optimisation Technician- Doncaster (IMOC Secretary)                    |
|                    |                                                      | Esoop Bharoocha (EB)       | SYICB Deputy Chief Pharmacist – Rotherham Hospital                                            |
| ✓                  |                                                      | Dean Eggitt (DE)           | LMC representative – Doncaster                                                                |
| ✓                  |                                                      | Rob Wise (RW)              | Senior Pharmacist NNICB - Bassetlaw Place Partnership                                         |
|                    |                                                      | Krishna Kasaraneni (KK)    | LMC Representative – Sheffield                                                                |
| ✓                  |                                                      | Lee Wilson (LW)            | Consultant Pharmacist DBTHFT                                                                  |
| ✓                  |                                                      | Sarah Hudson (SH)          | Deputy Chief Pharmacist SWYPFT                                                                |
|                    |                                                      | Joanne Wragg (JW)          | Sheffield Children's NHS FT Chief Pharmacist                                                  |
| ✓                  |                                                      | Barbara Obasi (BO)         | Senior Pharmacist (Pharmacy Integration and Development Portfolio)                            |
| ✓                  |                                                      | Abiola Allinson (AA)       | SYICB Chief Pharmacist- SHSC                                                                  |
| ✓                  |                                                      | Steve Davis (SD)           | RDaSH Chief Pharmacist                                                                        |
|                    |                                                      | Claire Thomas (CT)         | Community Pharmacy Clinical lead- SY ICB                                                      |
|                    |                                                      | Graham Marsh (GM)          | Sheffield Teaching Hospital Chief Pharmacist                                                  |
|                    |                                                      | Chidambaram Nathan (CN)    | Transplant and General surgery Consultant - STH                                               |
| ✓                  |                                                      | Trish Edney (TE)           | Sheffield Healthwatch Representative                                                          |
| ✓                  |                                                      | Eloise Summerfield (ES)    | Senior Pharmacist (Strategy & Delivery) Rotherham Place Support to High Cost Drugs (Pathways) |
| ✓                  |                                                      | Deborah Cooke (DC)         | Senior Pharmacist (Strategy and Delivery & Clinical Effectiveness- Barnsley Place)            |
|                    |                                                      | Gillian Turrell (GT)       | SYICB- Hospital Pharmacist- Barnsley                                                          |
|                    |                                                      | Sophie Holden (SH)         | Rotherham GP MM lead for Rotherham Place                                                      |
|                    |                                                      | Jason Page (JP)            | Rotherham Place Medical Director                                                              |
|                    |                                                      | Kathryn Horridge (KH)      | LMC Representative – Barnsley                                                                 |
| ✓                  |                                                      | Emily Parsons (EP)         | SY Medicines Safety Officer                                                                   |
| ✓                  |                                                      | Joanne Howlett (JH)        | Medicines Optimisation Lead Pharmacist (Strategy and Delivery – Barnsley Place)               |
|                    |                                                      | Paul McManus (PM)          | NHSE Specialist commissioning - Senior Pharmacist                                             |
| ✓                  |                                                      | Ewa Gabzdyl (EG)           | Senior Pharmacist Strategy & Delivery- Doncaster Place                                        |
|                    |                                                      | Surinder Ahuja (SA)        | Medication Safety Officer & Lead Pharmacist Governance and Formulary- Rotherham Hospital      |
| ✓                  |                                                      | Shameila Afsar -Baig (SAB) | Senior Pharmacist (Strategy and Delivery)- Sheffield Place                                    |
|                    |                                                      | Kulsoom Khan (KKh)         | Procurement Pharmacist at TRFT                                                                |
| ✓                  |                                                      | Mallicka Chakrabarty (MC)  | GP Prescribing Lead (Bassetlaw)                                                               |
|                    |                                                      | Navjit Johal (NJ)          | Chief Pharmacist – Rotherham Hospital                                                         |

|   |  |                     |                                        |
|---|--|---------------------|----------------------------------------|
| ✓ |  | Robina Okes-Voysey  | Senior Pharmacist, Quality Improvement |
| ✓ |  | Bipin Chandran (BC) | Rotherham LMC representative           |

|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Action |
|---|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| 1 | <b>Welcome:</b><br><br>Dr Bibipin Chandran- New Rotherham LMC representative<br><br>Jennifer Lynch - Rotherham Technician (induction)<br>Rumanaah Valli- Pharmacist (Induction)<br>Kamran Raoof- Pre Reg Pharmacy Technician (induction)<br>Joy Power - agenda item 7<br>Sharron Kebell- agenda item 10<br>Ebun Ojo - agenda item 9                                                                                                                                                                                                                                                                                                  |        |
|   | <b>Apologies</b><br><br>Chris Bland, Dr Sophie Holden, Joanne Wragg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |        |
| 2 | <b>Declarations of Interest (DOI)</b><br>The Chair reminded committee members of their obligation to declare any interest they may have on any issues arising at committee meetings which might conflict with the business of the South Yorkshire Integrated Care Board (ICB).<br><br>Declarations declared by members are listed in the ICB Register of Interests. The register is available on the ICB website at the following link: <a href="https://southyorkshire.icb.nhs.uk/about-us/our-structure/register-interests">https://southyorkshire.icb.nhs.uk/about-us/our-structure/register-interests</a><br><br>None were given |        |
| 3 | <b>Notification of Any Other Business</b><br><br>None were given                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |        |
| 4 | <b>Minutes of the meeting held on 4<sup>th</sup> June 2025</b><br><br>The committee approved the minutes to June's meeting. AH to circulate the minutes and upload to the IMOC website.                                                                                                                                                                                                                                                                                                                                                                                                                                              | AH     |
| 5 | <b>Action Log</b><br>The required actions were duly recorded in the action log.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |        |
| 6 | <b>ICB Formal Executive Group Report (FEG)</b><br><br>HT informed the committee that June's IMOC decisions went to the executive group meeting and were supportive of all the decisions                                                                                                                                                                                                                                                                                                                                                                                                                                              |        |

|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |    |
|---|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
|   | made. It was acknowledged that there is some nervousness around Risankizumab, further financial and alternative pathway information is being provided in July's Executive report. A decision will be made at next month's executive board meeting.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |    |
| 7 | <p><b>Tirzepatide type 2 diabetes guidance - Update on current guidance</b></p> <p>Strategy and Delivery Lead Pharmacist Joy Power presented to the committee a slight update on the already approved Tirzepatide type 2 diabetes guidance. Under the interaction section: oral contraceptives, previously the statement referred to the most common side effect on initiation of Tirzepatide is vomiting and is advised to for patients to switch to a non- oral method or add a barrier method of contraception. The statement has now been updated to <i>"One of the most common side effects of tirzepatide initiation is vomiting. Hence, it is advisable to switch to a non-oral contraceptive method or add a barrier method of contraception upon initiating tirzepatide therapy (for 4 weeks), or after each dose increase (for 4 weeks). Further information can be accessed in the <a href="#">Faculty of Sexual &amp; Reproductive Health statement</a>".</i></p> <p>Included in the update was information regarding hormone replacement therapy <i>"Tirzepatide delays gastric emptying and therefore may reduce the absorption of any oral component of HRT. Women taking oral HRT may be advised to switch to a non-oral therapy whilst using tirzepatide (Patch, IUD, vaginal progesterone (off license)) and for a minimum of 4 weeks after stopping tirzepatide. Further information is available in the <a href="#">British Menopause Society tools for clinicians</a> document."</i></p> <p>The committee approved the updated document. The chair thanked Joy for attending and the work gone into updating the document.</p> <p><b>Action:</b></p> <ul style="list-style-type: none"> <li>AH to version Tirzepatide type 2 diabetes guidance and replace current version on website.</li> </ul> | AH |
| 8 | <p><b>Tirzepatide for weight management FAQ for primary care clinicians</b></p> <p>HT reminded the committee of the NICE TA which was published on the 23<sup>rd</sup> December 2024 with a mandate that a commissioned service is to be available by the 23<sup>rd</sup> June 2025. Currently SY does not have a commissioned wrap around care for Tirzepatide for overweight and obesity established. NHS England were going to publicise that this could be available from your GP in the press. As GPs will likely be the 1<sup>st</sup> place patients would go and see about this treatment. With the current commissioning situation, the SY ICB</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |    |

|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |  |
|---|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
|   | <p>have prepared a Frequently Asked Questions (FAQ) paper to make it clear to primary care clinicians regarding the current situation and lack of commissioned service and for clinicians to be able to manage patient's expectations and answer any questions regarding treatment with tirzepatide. There is also a FAQ for patients which is available on the website, to advise patients on the current situation. There is an options appraisal paper being produced to consider the different pathways, this is very complex and expected to take several months but work is being completed in the background as quickly as possible. As part of the work the team will be engaging with providers and patients.</p> <p>The committee were happy that the document came to IMOC for information.</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |  |
| 9 | <p><b>Lipid modification in younger adults with T2DM</b></p> <p>Ebun Ojo (EOJ) clinical effectiveness senior pharmacist presented the committee with lipid modification in younger adults with T2DM. The original document was a Sheffield place guideline. There was a recent NICE update (NG28) which required the Sheffield document to be updated. The review of the document led to review other places documents and produce a SY guideline. It has been identified that type 2 diabetes in younger people is becoming more prevalent, and with current lifestyles they are at risk of cardiovascular disease (CVD) a lot earlier. The document helps primary care clinicians to be aware of the CVD risk and the flowchart identifies processes in place including baseline blood tests, medication and lifestyle changes. EOJ has engaged with different stakeholders and attended some place meetings and has amended the document to include the feedback given.</p> <p>It was noted by the committee if several changes could be made to the document:</p> <ul style="list-style-type: none"> <li>• The link to Sheffield weight loss is broken and to be amended to link to the SY documents</li> <li>• CG189 is now NG246</li> <li>• FH referral criteria link requires amending</li> <li>• Include links to Place documents</li> <li>• Direct link to diabetic resources making it quicker and easier for clinicians to refer to.</li> <li>• Instead of naming Atorvastatin changed to say offer a high intensity statin as it could be interpreted as Atorvastatin 20mg is the dose for all patients which is not always the case.</li> <li>• Under the section: Measuring central obesity the committee discussed that there is different circumference for different ethnic groups and gender and whether this should be</li> </ul> |  |

|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                 |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|
|    | <p>included in the document. It was agreed that it could be removed as there is already a link to the obesity guidelines.</p> <p>The committee approved of the SY Lipid modification in younger adults with T2DM documents subject to the above amendments. The chair thanked Ebun for attending IMOC and for all the work that has gone into preparing this document.</p> <p><b>Actions:</b></p> <ul style="list-style-type: none"> <li>• EOJ to make the required amendments</li> <li>• AH to host on the IMOC website</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | <p><b>EOJ</b><br/><b>AH</b></p> |
| 10 | <p><b>Acarizax and Grazax Shared Care Protocol (SCP) - Update current SCP</b></p> <p>Sharron Kebell high-cost drugs pathways pharmacist presented to the IMOC an updated Acarizax and Grazax SCP. NICE TA 1045 was published in March 2025.</p> <p>NICE recommends that use of house dust mite sublingual lyophilisate (SQ-HDM SLIT) (Acarizax<sup>®</sup>) as an option for treating moderate to severe house dust mite allergic rhinitis in people 12 to 65 years that is:</p> <ul style="list-style-type: none"> <li>◦ diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test or specific immunoglobulin E [IgE]) and</li> <li>◦ persistent despite use of symptom-relieving medicine.</li> </ul> <p>N.B. NICE do not recommend use in allergic asthma but acknowledge that some of the eligible population with house dust mite allergic rhinitis might also have allergic asthma which would not prevent them from having Acarizax<sup>®</sup> to treat their allergic rhinitis.</p> <p>The current SY SCP was updated with the SY and Bassetlaw logo and the updated NICE TA incorporated into the document. SY should not see an increase in patient numbers. SK informed the committee that the consultants are currently completing an in-depth audit of how many patients that are currently receiving the treatment. The committee queried around the wording, the difference between the licenced and the indication which is being commissioning within the SCP should made clear.</p> <p>The committee approved the new amendments to the current SCP, with the slight wording on page 3 to be amended by SK.</p> <p><b>Actions:</b></p> <ul style="list-style-type: none"> <li>• SK to amend the wording on page 3</li> <li>• AH to version and update SCP on IMOC website</li> </ul> | <p><b>SK</b><br/><b>AH</b></p>  |

|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |    |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 11 | <p><b>PolyPharmacy Structured Medication Reviews (SMR) resources</b></p> <p>HT informed the committee that the polypharmacy resources have been produced by Health Innovation Network. They have been done in collaboration with patients and have been endorsed nationally. The documents are available in multiply languages and in easy read format. The documents are useful tools to help support shared decision-making conversations with patients around polypharmacy and deprescribing during an SMR. Empowering patients to ask the right questions and give them written information as part of the shared decision-making process. Patients to understand why they might have stopped some of their medications. The documents will be hosted on the IMOC website and will be reviewed by the subgroup and AH if there have been any updates/ changes to the documents. The committee discussed how the resources will be used in practice setting as it will not be possible to print out the leaflets and send them to patients as it is not cost effective. HT discussed that there are electronic resources which can be used to share the resources via AccuRx SMS. The committee were happy to endorse the resources documents which will be hosted on the IMOC website.</p> <p><b>Action:</b></p> <ul style="list-style-type: none"> <li>• AH to upload the resource documents onto the IMOC website</li> </ul> | AH |
| 12 | <p><b>NICE Summary</b></p> <ul style="list-style-type: none"> <li>• NICE TA1065- Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency- already traffic lighted as Red on SY TLDL</li> <li>• NICE TA1066- Somapacitan for treating growth hormone deficiency in people 3 to 17 years- Currently traffic lighted as Grey now traffic lighted as Red on SY TLDL</li> <li>• NICE TA1067-Linzagolix for treating symptoms of endometriosis- Clinical lead of MOT to review traffic lighted as Red on SY TLDL</li> <li>• NICE TA1068-Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy- Terminated appraisal traffic lighted as Grey on SY TLDL</li> <li>• NICE TA1069-Efgartigimod for treating antibody-positive generalised myasthenia gravis- Traffic Lighted as Grey on SY TLDL</li> <li>• NICE TA 1070-Spesolimab for treating generalised pustular psoriasis flares- Currently traffic lighted as Grey now traffic lighted as Red on SY TLDL</li> </ul>                                                                                                                                                                                                                                                                                                       |    |

|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |  |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
|    | <ul style="list-style-type: none"> <li>NICE TA 1071- Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer- Currently traffic lighted as Red on SY TLDL</li> <li>NICE TA 1072-Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy- Terminated appraisal traffic lighted as Grey on SY TLDL</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |  |
| 13 | <p><b>Safety updates</b></p> <p>EP informed the committee with the below safety updates</p> <ul style="list-style-type: none"> <li><b>Class 2 Medicines Recall: Paracetamol 500mg Tablets</b><br/>Chelonia Healthcare Limited is recalling specific batches of Paracetamol 500mg Tablets (100 pots) as a precautionary measure due to contamination following a small number of complaints of discoloured tablets within the pots.<br/><br/>- These tablets can only be obtained from a pharmacy with a prescription. The tablets should be 'white capsule-shaped tablets, scored on one side'. If any tablets found that are discoloured in any way, in pots from the listed batches, patients are advised to contact the community pharmacy that dispensed the prescription.</li> <li><b>Valproate: updated safety and educational materials to support patient discussion on reproductive risks</b><br/>Updated safety and educational materials are now available to support the implementation of the regulatory measures announced in the November 2023 National Patient Safety Alert and the September 2024 Drug Safety Update. They also include previous updates to product information on the risk of low birth weight in children exposed to valproate during pregnancy.<br/><br/>-EP is amending local guidance's with updated links and information if required.</li> <li><b>Class 2 Medicines Recall: Inhixa 12,000IU (120mg)/0.8mL solution for injection</b><br/>Maxearn Limited have informed the MHRA that the carton used to package two imported batches of Inhixa have been released to the market with a typographical error on one side of the carton. The incorrect strength states "12,000 IU (20mg)/0.8 ml solution for injection" instead of the correct strength "12,000 IU (120mg)/0.8 ml solution for injection".<br/><br/>-For information: Open prescribing shows 1 item prescribed in SY ICB in March 2025; 19 items in the last 12m.<br/>Pharmacists who have been supplied this batch and suspect they have dispensed the medicine to patients should contact the patient immediately to make them aware of this error.<br/>Patients who have been prescribed Inhixa 2,000 IU (20mg)/0.2 mL should check the batch number of their pre-</li> </ul> |  |

|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |     |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
|    | <p>filled syringes - any that have received the affected batches of 120mg/0.8ml have should contact their pharmacist or GP immediately.</p> <ul style="list-style-type: none"> <li> <b>GLP-1 medicines for weight loss and diabetes: what you need to know</b><br/>           Following concerns these medicines are not being used safely, the MHRA has issued guidance for patients covering their uses, where to obtain them, risks, contraception and pregnancy, breastfeeding, depression or suicidal thoughts, and use around the time of surgery or an operation.<br/> <a href="#">-GLP-1 medicines for weight loss and diabetes: what you need to know</a> provides a good summary of key safety information that can be shared with patients.         </li> <li> <b>Senokot (sennoside or senna fruit extract, senna pods tinnevelly) products</b><br/>           Use in pregnancy and lactation is now contraindicated. Experimental data suggests genotoxic risk of several anthranoids (e.g. emodin, aloe emodin). And following administration, active metabolites of anthranoids (e.g. rhein) were excreted in breast milk in small amounts.<br/><br/>           -The contraindication currently only applies to the Senokot brand. The BNF states: <i>Specialist sources indicate suitable for use in pregnancy.</i> BUMPS information leaflet on constipation currently states '<i>Senna (Senokot®) stimulates the bowel muscles, helping to move stools along. One study showed that use of senna during the first twelve weeks of pregnancy (while the baby is developing) is not linked to birth defects.</i>' No warning on clinical systems for Senokot products.         </li> </ul> <p><b>Action:</b></p> <ul style="list-style-type: none"> <li>MOT to take back to Place meetings to review and action as recommended in the safety update</li> </ul> |     |
| 14 | <p><b>Horizon Scanning</b></p> <p>All drugs included in the list were approved and recorded in the summary below. Highlighting Optimise Rx and Script switch can be used to notify prescribers with recommendations required.</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | MOT |



|    |                                                                                                                                                                                                                                                                                                                                                             |  |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| 15 | <b>IMOC subgroup TLDL</b><br><br>All drugs included in the list were approved and recorded in the summary below.                                                                                                                                                                                                                                            |  |
| 16 | <b>Minutes from SY ICB place APCs</b><br>None were discussed                                                                                                                                                                                                                                                                                                |  |
| 17 | <b>Stock Shortages</b><br>- Gliptin shortages- current QIPP work is on hold.<br>Strategy and delivery team are closely monitoring the stock situation.                                                                                                                                                                                                      |  |
| 18 | <b>Items for Escalation (e.g. commissioning requirements)</b>                                                                                                                                                                                                                                                                                               |  |
| 19 | <b>Workplan / Forward Planner/ action log</b><br>Updated as required<br>AJM asked the committee to consider reviewing formulary recommendations going forward given the new model of the ICB operations. Possibly to be discussed at September's meeting once the ICB has concluded its consultation process.<br>This will be added to the forward planner. |  |
| 20 | <b>Any other Business</b><br><br>AH conducted a Poll during the meeting to established if quoracy would be met for August's IMOC meeting. The poll concluded that there would be enough members present to meet quoracy requirements.                                                                                                                       |  |
| 21 | <b>Date and Time of Next Meeting</b><br>Wednesday 6 <sup>th</sup> August 2025 11:30am Via Microsoft Team                                                                                                                                                                                                                                                    |  |

**Summary Points and Recommendations approved**  
**July 2025**

|                                           |                     |                                                                                                                                                                                                                                                                                                                                                               |                            |                   |                 |
|-------------------------------------------|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|-------------------|-----------------|
| <b>Shared care/Prescribing Guidelines</b> |                     | <ul style="list-style-type: none"> <li>• Tirzepatide type 2 diabetes guidance - Update on current guidance</li> <li>• Tirzepatide for weight management FAQ for primary care Clinicians</li> <li>• SY Lipid modification in younger adults with T2DM</li> <li>• Acarizax and Grazax SCP - Update current SCP</li> <li>• PolyPharmacy SMR resources</li> </ul> |                            |                   |                 |
| <b>Traffic Light status</b>               | <b>Drug/Product</b> | <b>Brand name</b>                                                                                                                                                                                                                                                                                                                                             | <b>Rational / criteria</b> | <b>Indication</b> | <b>Comments</b> |
|                                           |                     |                                                                                                                                                                                                                                                                                                                                                               |                            |                   |                 |

|       |                                                                     |             |     |                                                                                                                                                                                                                                                                                                                                                    |                                                                          |
|-------|---------------------------------------------------------------------|-------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|
|       |                                                                     |             |     |                                                                                                                                                                                                                                                                                                                                                    |                                                                          |
| Red   | Bevacizumab gamma (new ophthalmic formulation)                      |             | 1   | Use in adults for treatment of neovascular (wet) age-related macular degeneration                                                                                                                                                                                                                                                                  | <a href="#">NICE TA 1022</a>                                             |
| Red   | Nemolizumab (new medicine)                                          |             |     | Treatment of moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors in adults and adolescents aged ≥12 years with a body weight ≥30 kg, who are candidates for systemic therapy, and treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy | <a href="#">To classify when NICE TA published as expected July 2025</a> |
| Grey  | Sumatriptan + naproxen sodium (new combination formulation)         |             | 4,7 | Acute treatment of the headache phase of migraine attacks with or without aura in adults where treatment with a mono-entity product has been insufficient                                                                                                                                                                                          |                                                                          |
| Grey  | Ruxolitinib (new topical formulation with new indication)           |             | 6   | Treatment of non-segmental vitiligo with facial involvement in adults and adolescents aged ≥12 years                                                                                                                                                                                                                                               | <a href="#">NICE TA in development</a>                                   |
| Green | Sildenafil citrate ( <i>new orodispersible tablet formulation</i> ) |             |     | Use in adult men with erectile dysfunction                                                                                                                                                                                                                                                                                                         | <i>Sildenafil, generic, for erectile dysfunction is already green</i>    |
| Red   | Epoprostenol                                                        |             | 1,6 | pulmonary arterial hypertension, to prevent blood clotting during kidney dialysis in emergency situations                                                                                                                                                                                                                                          |                                                                          |
| Red   | Etanercept                                                          |             | 1,6 | In line with recommended NICE TA's                                                                                                                                                                                                                                                                                                                 | <a href="#">Etanercept NICE information</a>                              |
| Red   | Etelcalcetide                                                       |             | 1   | In line with recommended NICE TA's                                                                                                                                                                                                                                                                                                                 | <a href="#">Etelcalcetide NICE information</a>                           |
| Red   | Etoposide                                                           |             | 1   | In line with recommended NICE TA's                                                                                                                                                                                                                                                                                                                 | <a href="#">Etoposide NICE information</a>                               |
| Red   | Etravirine                                                          |             | 1,6 | HIV infection.                                                                                                                                                                                                                                                                                                                                     |                                                                          |
| Red   | European Viper Venom Antiserum                                      |             | 1   | European Adder bite                                                                                                                                                                                                                                                                                                                                |                                                                          |
| Red   | Everolimus                                                          |             | 1,6 | In line with recommended NICE TA's                                                                                                                                                                                                                                                                                                                 | <a href="#">Everolimus NICE information</a>                              |
| Red   | Evolocumab                                                          |             | 1,6 | In line with recommended NICE TA's                                                                                                                                                                                                                                                                                                                 | <a href="#">Evolocumab NICE information</a>                              |
| Red   | Ex vivo expanded autologous human corneal                           | (Holoclar®) | 1,6 | In line with recommended NICE TA's                                                                                                                                                                                                                                                                                                                 | <a href="#">Holoclar NICE information</a>                                |

|      |                                                                |            |     |                                                                                                                                                                   |                                                                              |
|------|----------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|
|      | epithelial cells containing stem cells                         |            |     |                                                                                                                                                                   |                                                                              |
| Red  | Factor VIIa, Factor VIII, Factor IX, Factor XIII               |            | 1,6 | Haemorrhage in patients with haemophilia A or B with antibodies to factors VIII or IX, acquired haemophilia, factor VII deficiency, or Glanzmann's thrombasthenia |                                                                              |
| Red  | Faricimab                                                      |            | 1   | In line with recommended NICE TA's                                                                                                                                | <a href="#">Faricimab NICE information</a>                                   |
| Red  | Fedratinib                                                     |            | 1,6 | In line with recommended NICE TA's                                                                                                                                | <a href="#">Fedratinib NICE information</a>                                  |
| Red  | Fenfluramine                                                   |            | 1,6 | In line with recommended NICE TA's                                                                                                                                | <a href="#">Fenfluramine NICE information</a>                                |
| Red  | Ferric carboxymaltose                                          |            | 1   | Iron deficiency when oral iron preparations are ineffective or cannot be used.                                                                                    | -                                                                            |
| Red  | Fibrin sealants                                                |            | 1   | Treatment and prophylaxis of haemorrhage                                                                                                                          | -                                                                            |
| Red  | Fibrinogen                                                     |            | 1,6 | As per BCSH guidelines for specialist indications                                                                                                                 | -                                                                            |
| Red  | Filgotinib                                                     |            | 1   | In line with recommended NICE TA's                                                                                                                                | <a href="#">Filgotinib NICE information</a>                                  |
| Red  | Filgrastim                                                     |            | 1   | Neutropenia                                                                                                                                                       | -                                                                            |
| Red  | Fingolimod                                                     |            | 1,6 | In line with recommended NICE TA's                                                                                                                                | <a href="#">Fingolimod NICE information</a>                                  |
| Red  | Fluocinolone acetonide intravitreal implant                    | (Iluvien®) | 1   | In line with recommended NICE TA's                                                                                                                                | <a href="#">Fluocinolone acetonide intravitreal implant NICE information</a> |
| Red  | Follitropin alfa, beta, delta & Follitropin alfa/lutropin alfa |            | 1   | IVF                                                                                                                                                               |                                                                              |
| Red  | Fomepizole                                                     |            | 1   | Emergency Treatment of Poisoning (ethylene glycol or methanol poisoning)                                                                                          |                                                                              |
| Red  | Fondaparinux                                                   |            | 1   | Acute coronary syndromes, NSTEMI, angina                                                                                                                          |                                                                              |
| Red  | Fosamprenavir                                                  |            | 1,6 | HIV infection.                                                                                                                                                    |                                                                              |
| Grey | Erdosteine                                                     |            | 3   | Symptomatic treatment of acute exacerbations of chronic bronchitis                                                                                                |                                                                              |

|              |                                                                           |  |       |                                                                                                                               |                                                                                                               |
|--------------|---------------------------------------------------------------------------|--|-------|-------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|
| <b>Green</b> | Tadalafil 5mg (daily )                                                    |  |       |                                                                                                                               | Refer to place based formularies for further details already traffic lighted as Green add wording for clarity |
| <b>Red</b>   | Nivolumab plus ipilimumab                                                 |  | 1,6   | for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | NICE TA1065 currently already traffic lighted as Red on SY TLDL                                               |
| <b>Red</b>   | Somapacitan                                                               |  | 1     | Somapacitan for treating growth hormone deficiency in people 3 to 17 years                                                    | NICE TA 1066                                                                                                  |
| <b>Red</b>   | Linzagolix                                                                |  | 1     | Linzagolix for treating symptoms of endometriosis                                                                             | NICE TA 1067 MO clinical lead is reviewing                                                                    |
| <b>Grey</b>  | Tislelizumab                                                              |  | 7     | Terminated appraisals                                                                                                         | NICE TA 1067                                                                                                  |
| <b>Grey</b>  | Efgartigimod for treating antibody-positive generalised myasthenia gravis |  | 2     | Efgartigimod for treating antibody-positive generalised myasthenia gravis                                                     | NICE TA 1068&TA1072-terminated appraisals                                                                     |
| <b>Red</b>   | Spesolimab                                                                |  | 1,3,6 | Spesolimab for treating generalised pustular psoriasis flares                                                                 | NICE TA 1070                                                                                                  |
| <b>Red</b>   | Atezolizumab                                                              |  | 1,6   | Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer                                                    | NICE TA1071 already traffic lighted as red                                                                    |